Click for more information

0.00% 14.0¢

DIMERIX LIMITED

Dimerix Limited is an Australia-based clinical-stage biopharmaceutical company. The... Dimerix Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on developing new therapies in areas with unmet medical needs for global markets. It is focused on developing its products, DMX-200, for focal segmental glomerulosclerosis (FSGS), respiratory complications associated with COVID-19 and diabetic kidney disease, and DMX-700 for chronic obstructive pulmonary disease (COPD). Its DMX-200 and DMX-700 are identified using its assay, Receptor Heteromer Investigation Technology (Receptor-HIT), which is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. It has progressed to Phase III studies in FSGS, COVID-19 pneumonia feasibility and respiratory complications associated with COVID-19 feasibility. It is also planning for the next development stage in diabetic kidney disease and enters pre-clinical studies with DMX-700 for COPD.More